Hybrid closed‐loop insulin delivery improves glycaemic control compared with sensor‐augmented pump therapy: A meta‐analysis of ‘free‐living’ randomised trials in type 1 diabetes
Authors' conclusion
Our findings support HCLS as a superior modality to SAP therapy in improving glycaemic control, particularly in paediatric populations. HCLS effectively reduces hyperglycaemia and increases TIR, with modest effects on hypoglycaemia. The clinical implications are significant, highlighting the advantages of HCLS in optimising glucose regulation and mitigating glycaemic variability. This technology offers improved glycaemic control and enhanced quality of life for people living with type 1 diabetes.
Study context
- Population
- People with T1D in free-living randomised controlled trials (RCTs) and randomised crossover trials27 studies · >1000 participants
- Comparison
- HCL systems vs sensor-augmented pump therapy
- Outcome
- Glycaemic control, glucose variability and TIR
Methodological detailsRCTs and randomised crossover trials
- RCTs and randomised crossover trials
Pooled result
As reported in the abstract
Reduction in mean glucose
2.0 mg/dL
lower with hybrid closed-loop systems (HCLS)
Increase in time in range (TIR)
8.8%
Glycaemic control
Further pooled results
Hyperglycaemia (time above range)
- Reduction in time >10 mmol/L with HCLS
- 7.8%
- Reduction in time >13.9 mmol/L with HCLS
- 3.63%
- Reduction in time >16.7 mmol/L with HCLS
- 0.88%
Hypoglycaemia (time below range)
- Reduction in time <3 mmol/L with HCLS
- 0.10%
- Reduction in time <3.9 mmol/L with HCLS
- 0.72%
- Modest improvements
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →